Jane Street Group LLC purchased a new position in shares of Pharvaris (NASDAQ:PHVS - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 28,418 shares of the company's stock, valued at approximately $526,000. Jane Street Group LLC owned 0.09% of Pharvaris at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in PHVS. Novo Holdings A S increased its position in shares of Pharvaris by 47.7% during the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company's stock worth $32,430,000 after acquiring an additional 556,970 shares during the last quarter. Deerfield Management Company L.P. Series C grew its stake in Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company's stock valued at $26,269,000 after purchasing an additional 335,687 shares in the last quarter. Patient Square Capital LP purchased a new stake in Pharvaris during the 3rd quarter worth approximately $4,488,000. State Street Corp acquired a new position in shares of Pharvaris in the 3rd quarter valued at approximately $1,000,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pharvaris during the 3rd quarter valued at approximately $906,000.
Pharvaris Stock Performance
Shares of PHVS stock traded down $0.47 during mid-day trading on Monday, reaching $18.06. 21,885 shares of the company were exchanged, compared to its average volume of 58,295. The business's 50 day simple moving average is $20.59 and its 200 day simple moving average is $19.36. The company has a market capitalization of $575.03 million, a P/E ratio of -6.45 and a beta of -3.06. Pharvaris has a fifty-two week low of $15.37 and a fifty-two week high of $33.00.
Pharvaris Profile
(
Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
